Subject: Another Day of Double-Digit Gains for Positive ID

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
Another Day of Double-Digit Gains for Positive ID
Hot Stock to WatchHot Stock to Watch

Company: PositiveID Corporation (OTCQB: PSID)


Price: 0.0449

Change (%): + 0.0065 (16.93)

Volume: 16,952,348
PSID Chart

PositiveID Provides Mid-Year Update and Highlights Its Progress With Firefly Dx Development

Firefly Dx Prototype System is Consistently Performing PCR and Accurately Detecting Pathogens in Less Than 20 Minutes

DELRAY BEACH, Fla., June 29, 2015 (GLOBE NEWSWIRE) - PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a developer of biological detection and diagnostics solutions, provided a mid-year update today to its shareholders and highlighted its progress with the testing of the Firefly Dx prototype PCR (polymerase chain reaction) pathogen detection system.

Mid-Year 2015 Highlights
  • Completed the design of the second-phase (bench-top) prototype of Firefly Dx, and commenced building the second-phase prototype of Firefly Dx
  • Prepared additional M-BAND (Microfluidic Bioagent Autonomous Network Detector) systems for field deployment and testing
  • Completed the build of its Firefly Dx PCR chip, and started testing assays to prove the design of achieving PCR results in less than 20 minutes
  • Filed two U.S. patents for Firefly Dx: “A Cyclical and Continuous Flow PCR Device,” which covers a cyclical mechanism of thermal cycling required to complete real-time PCR and deliver results in less than 20 minutes, and “A Cyclical PCR Device with Reusable Heat Zones”
  • Detected multiple organisms with a multiplex assay designed to simultaneously test for up to four pathogens on the Firefly Dx PCR chip
  • Successfully detected influenza, which is an RNA virus and requires a reverse transcription step to create cDNA prior to PCR being performed, on its Firefly Dx prototype system
  • Entered a co-marketing agreement with DirectView Security Systems, Inc., a provider of video surveillance systems including body worn cameras, to jointly market the companies’ products to homeland security and first responders
  • Successfully tested 12 different assays, both its own and third-party assays, on Firefly Dx prototype system, detecting all the pathogens it tested
  • Issued revenue guidance of 3-6 million dollars for 2015
  • Successfully completed testing of M-BAND under the Department of Defense JUPITR program
  • Continued progress under the Phase I SenseNet contract under the Department of Homeland Security
“As we reach the middle of 2015, we are very pleased with the advancements we’ve made to our Firefly Dx prototype system, and we will continue to expand our testing and challenge the system to present data to potential partners and future customers,” stated William J. Caragol, Chairman and CEO of PositiveID. “We believe that our accomplishments in the first half of 2015 set up PositiveID for continued exciting developments through the end of 2015 and into 2016 and are affirming our revenue guidance of 3-6 million dollars for 2015.”

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks